Insider · CIK 0001860609

Patel Sushil

Reports to the SEC for 2 companies · WOBURN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001860609

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-10	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−39.3K sh	$12.97	−$510K	708,151
2026-06-29	RVMDRevolution Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,955 sh	$37.54	+$111K	27,236
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−300 sh	$183.17	−$55K	26,936
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−900 sh	$184.59	−$166K	26,036
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−1,100 sh	$185.90	−$204K	24,936
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−858 sh	$186.92	−$160K	24,078
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−300 sh	$187.83	−$56.3K	23,778
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−100 sh	$188.57	−$18.9K	23,678
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−600 sh	$190.54	−$114K	23,078
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−541 sh	$191.87	−$104K	22,537
2026-06-29	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−881 sh	$192.61	−$170K	21,656
2026-06-29	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,955 sh	—	—	13,000
2026-06-18	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+1,191 sh	—	—	24,281
2026-06-18	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,127 sh	—	—	3,127
2026-05-18	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−37.3K sh	$5.08	−$190K	747,492
2026-04-01	REPLReplimune Group, Inc.A Award	Director, Chief Executive Officer	AAward	+251K sh	—	—	784,816
2026-04-01	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+377K sh	—	—	376,860
2025-12-19	REPLReplimune Group, Inc.A Award	Director, Chief Executive Officer	AAward	+200K sh	—	—	533,576
2025-12-02	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−10K sh	$11.13	−$111K	333,576
2025-06-26	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+3,142 sh	—	—	23,090
2025-06-26	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+11.6K sh	—	—	11,574
2025-05-20	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−25.1K sh	$8.06	−$202K	343,576
2025-04-01	REPLReplimune Group, Inc.A Award	Director, Chief Executive Officer	AAward	+167K sh	—	—	368,681
2025-04-01	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+250K sh	—	—	250,000
2024-12-16	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−10K sh	$12.42	−$124K	202,014
2024-10-31	RVMDRevolution Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$24.84	+$124K	24,948
2024-10-31	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−5,000 sh	$54.14	−$271K	19,948
2024-10-31	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	13,400
2024-07-09	RVMDRevolution Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,155 sh	$16.80	+$36.2K	22,103
2024-07-09	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−2,155 sh	$44.00	−$94.8K	19,948
2024-07-09	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,155 sh	—	—	32,490
2024-06-20	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+4,800 sh	—	—	20,500
2024-06-20	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.7K sh	—	—	16,700
2024-06-20	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+4,248 sh	—	—	19,948
2024-06-20	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	15,955
2024-05-16	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−20.2K sh	$6.47	−$131K	212,014
2024-04-10	RVMDRevolution Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,155 sh	$16.80	+$36.2K	17,855
2024-04-10	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	−2,155 sh	$37.00	−$79.7K	15,700
2024-04-10	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,155 sh	—	—	34,645
2024-04-01	REPLReplimune Group, Inc.A Award	Director, Chief Executive Officer	AAward	+83.3K sh	—	—	232,208
2024-04-01	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+250K sh	—	—	250,000
2023-06-13	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−5,145 sh	$24.11	−$124K	149,426
2023-06-13	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−553 sh	$23.44	−$13K	148,873
2023-06-08	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+5,200 sh	—	—	15,700
2023-06-08	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.4K sh	—	—	18,400
2023-05-16	REPLReplimune Group, Inc.S Sale	Director, Chief Executive Officer	SSale	−15.6K sh	$18.05	−$281K	154,571
2023-04-01	REPLReplimune Group, Inc.A Award	Director, Chief Executive Officer	AAward	+40K sh	—	—	170,146
2023-04-01	REPLReplimune Group, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+60K sh	—	—	60,000
2022-06-16	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+10.5K sh	—	—	10,500
2022-06-16	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+36.8K sh	—	—	36,800

Recent filings

Accepted (ET)
Aug 124
Patel Sushil0001104659-26-095012
SEC(opens sec.gov)
Jul 14
Patel Sushil0001610717-26-000311
SEC(opens sec.gov)
Jun 234
Patel Sushil0001610717-26-000284
SEC(opens sec.gov)
May 204
Patel Sushil0001104659-26-064519
SEC(opens sec.gov)
Apr 74
Patel Sushil0001104659-26-040571
SEC(opens sec.gov)
Dec 194
Patel Sushil0001104659-25-123290
SEC(opens sec.gov)
Dec 44
Patel Sushil0001104659-25-118483
SEC(opens sec.gov)
Jun 304
Patel Sushil0001610717-25-000272
SEC(opens sec.gov)

Companies

Address

C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE, SUITE 303

WOBURN, MA, 01801